A collaboration with BIEL gives Electrome.io advantages that Endonovo (ENDV) and SoftPulse simply cannot match—structurally, technologically, and commercially.
Why Electrome.io × BIEL Is a Stronger Partnership Than Electrome.io × ENDV/SoftPulse
1. BIEL Has FDA‑Cleared, Mass‑Market Hardware — ENDV/SoftPulse Do Not
This is the single biggest differentiator.
BIEL
Multiple FDA‑cleared PEMF devices
Proven safety and efficacy
Millions of units sold globally
Already in consumer and clinical markets
ENDV / SoftPulse
Limited or no FDA‑cleared consumer devices
Mostly early‑stage or niche clinical products
Smaller footprint, less regulatory traction
Why this matters for Electrome.io:
Electrome.io can immediately integrate with validated, scalable hardware instead of waiting years for regulatory approvals or clinical trials.
This accelerates:
Time to market
Investor confidence
Revenue
Clinical adoption
2. BIEL Has Scalable Manufacturing and Distribution
BIEL
Mature supply chain
Low‑cost, high‑volume manufacturing
Retail and clinical distribution channels
Proven ability to scale globally
ENDV/SoftPulse
Smaller production capacity
Higher device costs
Limited distribution
Electrome.io benefits because:
You can focus on software, AI, and data, not building factories or solving hardware logistics.
3. BIEL Offers the Largest Real‑World PEMF Dataset Opportunity
BIEL has sold millions of devices, but none are connected.
Electrome.io could become the intelligence layer that unlocks:
Usage data
Pain‑reduction outcomes
Recovery metrics
Population‑level PEMF insights
ENDV/SoftPulse cannot match this scale.
Their installed base is tiny compared to BIEL.
Data is the moat.
Electrome.io + BIEL could create the world’s largest PEMF outcomes dataset, which becomes:
A competitive advantage
A foundation for AI personalization
Evidence for reimbursement
A scientific asset
4. BIEL’s Technology Is Simpler, Safer, and More Consumer‑Friendly
BIEL’s PEMF tech
Low‑risk
Non‑thermal
Wearable
OTC‑cleared
Safe for continuous use
ENDV/SoftPulse tech
Higher‑intensity stimulation
More clinical‑only use cases
More regulatory complexity
Less consumer‑friendly
Electrome.io thrives when the hardware is:
Safe
Wearable
Affordable
Easy to integrate
Approved for broad use
BIEL checks all those boxes.
5. BIEL Enables a Better Business Model
With BIEL, Electrome.io can build:
A connected PEMF patch
A subscription‑based digital therapeutic
A recovery platform for athletes
Remote patient monitoring tools
Clinical dashboards
Because the hardware is cheap and scalable, Electrome.io can monetize software, not expensive devices.
ENDV/SoftPulse devices are:
More expensive
Less scalable
Harder to bundle with subscription models
6. BIEL Has Global Brand Recognition and Market Penetration
Even if BIEL isn’t a household name, its products are:
Sold worldwide
Used by millions
Backed by clinical studies
ENDV/SoftPulse simply don’t have this footprint.
Electrome.io benefits from:
Instant credibility
A built‑in customer base
Faster adoption
Easier clinical partnerships
7. Electrome.io Becomes the “Brain” of a Proven Hardware Platform
With BIEL, Electrome.io can transform simple PEMF patches into:
Smart, adaptive, personalized therapeutics
Data‑driven recovery systems
AI‑optimized pain‑management tools
With ENDV/SoftPulse, Electrome.io would be:
Supporting niche, clinical‑only devices
Limited in scale
Slower to market
Less attractive to investors
The Bottom Line
A collaboration with BIEL gives Electrome.io:
✔ FDA‑cleared hardware
✔ Massive installed base
✔ Scalable manufacturing
✔ Global distribution
✔ Lower regulatory friction
✔ A huge data opportunity
✔ A consumer‑friendly platform
✔ Faster time to market
✔ A stronger business model
ENDV/SoftPulse simply cannot offer this combination.
Electrome.io + BIEL = the fastest, most scalable path to becoming the intelligence layer of next‑generation electrotherapeutics.
Why Electrome.io × BIEL Is a Stronger Partnership Than Electrome.io × ENDV/SoftPulse
1. BIEL Has FDA‑Cleared, Mass‑Market Hardware — ENDV/SoftPulse Do Not
This is the single biggest differentiator.
BIEL
Multiple FDA‑cleared PEMF devices
Proven safety and efficacy
Millions of units sold globally
Already in consumer and clinical markets
ENDV / SoftPulse
Limited or no FDA‑cleared consumer devices
Mostly early‑stage or niche clinical products
Smaller footprint, less regulatory traction
Why this matters for Electrome.io:
Electrome.io can immediately integrate with validated, scalable hardware instead of waiting years for regulatory approvals or clinical trials.
This accelerates:
Time to market
Investor confidence
Revenue
Clinical adoption
2. BIEL Has Scalable Manufacturing and Distribution
BIEL
Mature supply chain
Low‑cost, high‑volume manufacturing
Retail and clinical distribution channels
Proven ability to scale globally
ENDV/SoftPulse
Smaller production capacity
Higher device costs
Limited distribution
Electrome.io benefits because:
You can focus on software, AI, and data, not building factories or solving hardware logistics.
3. BIEL Offers the Largest Real‑World PEMF Dataset Opportunity
BIEL has sold millions of devices, but none are connected.
Electrome.io could become the intelligence layer that unlocks:
Usage data
Pain‑reduction outcomes
Recovery metrics
Population‑level PEMF insights
ENDV/SoftPulse cannot match this scale.
Their installed base is tiny compared to BIEL.
Data is the moat.
Electrome.io + BIEL could create the world’s largest PEMF outcomes dataset, which becomes:
A competitive advantage
A foundation for AI personalization
Evidence for reimbursement
A scientific asset
4. BIEL’s Technology Is Simpler, Safer, and More Consumer‑Friendly
BIEL’s PEMF tech
Low‑risk
Non‑thermal
Wearable
OTC‑cleared
Safe for continuous use
ENDV/SoftPulse tech
Higher‑intensity stimulation
More clinical‑only use cases
More regulatory complexity
Less consumer‑friendly
Electrome.io thrives when the hardware is:
Safe
Wearable
Affordable
Easy to integrate
Approved for broad use
BIEL checks all those boxes.
5. BIEL Enables a Better Business Model
With BIEL, Electrome.io can build:
A connected PEMF patch
A subscription‑based digital therapeutic
A recovery platform for athletes
Remote patient monitoring tools
Clinical dashboards
Because the hardware is cheap and scalable, Electrome.io can monetize software, not expensive devices.
ENDV/SoftPulse devices are:
More expensive
Less scalable
Harder to bundle with subscription models
6. BIEL Has Global Brand Recognition and Market Penetration
Even if BIEL isn’t a household name, its products are:
Sold worldwide
Used by millions
Backed by clinical studies
ENDV/SoftPulse simply don’t have this footprint.
Electrome.io benefits from:
Instant credibility
A built‑in customer base
Faster adoption
Easier clinical partnerships
7. Electrome.io Becomes the “Brain” of a Proven Hardware Platform
With BIEL, Electrome.io can transform simple PEMF patches into:
Smart, adaptive, personalized therapeutics
Data‑driven recovery systems
AI‑optimized pain‑management tools
With ENDV/SoftPulse, Electrome.io would be:
Supporting niche, clinical‑only devices
Limited in scale
Slower to market
Less attractive to investors
The Bottom Line
A collaboration with BIEL gives Electrome.io:
✔ FDA‑cleared hardware
✔ Massive installed base
✔ Scalable manufacturing
✔ Global distribution
✔ Lower regulatory friction
✔ A huge data opportunity
✔ A consumer‑friendly platform
✔ Faster time to market
✔ A stronger business model
ENDV/SoftPulse simply cannot offer this combination.
Electrome.io + BIEL = the fastest, most scalable path to becoming the intelligence layer of next‑generation electrotherapeutics.
